Xiexin Tang ameliorates dyslipidemia in high-fat diet-induced obese rats via elevating gut microbiota-derived short chain fatty acids production and adjusting energy metabolism.
Identifieur interne : 000181 ( Main/Exploration ); précédent : 000180; suivant : 000182Xiexin Tang ameliorates dyslipidemia in high-fat diet-induced obese rats via elevating gut microbiota-derived short chain fatty acids production and adjusting energy metabolism.
Auteurs : Suwei Xiao [République populaire de Chine] ; Zhimiao Zhang [République populaire de Chine] ; Mengjun Chen [République populaire de Chine] ; Junfeng Zou [République populaire de Chine] ; Shu Jiang [République populaire de Chine] ; Dawei Qian [République populaire de Chine] ; Jinao Duan [République populaire de Chine]Source :
- Journal of ethnopharmacology [ 1872-7573 ] ; 2019.
Descripteurs français
- KwdFr :
- Acides gras volatils (métabolisme), Agents antiobésité (pharmacologie), Agents antiobésité (usage thérapeutique), Alimentation riche en graisse (MeSH), Animaux (MeSH), Dyslipidémies (anatomopathologie), Dyslipidémies (microbiologie), Dyslipidémies (métabolisme), Dyslipidémies (traitement médicamenteux), Foie (anatomopathologie), Foie (effets des médicaments et des substances chimiques), Hypolipémiants (pharmacologie), Hypolipémiants (usage thérapeutique), Microbiome gastro-intestinal (MeSH), Mâle (MeSH), Médicaments issus de plantes chinoises (pharmacologie), Médicaments issus de plantes chinoises (usage thérapeutique), Métabolisme énergétique (effets des médicaments et des substances chimiques), Obésité (anatomopathologie), Obésité (microbiologie), Obésité (métabolisme), Obésité (traitement médicamenteux), Rat Sprague-Dawley (MeSH), Tissu adipeux (anatomopathologie), Tissu adipeux (effets des médicaments et des substances chimiques).
- MESH :
- anatomopathologie : Dyslipidémies, Foie, Obésité, Tissu adipeux.
- effets des médicaments et des substances chimiques : Foie, Métabolisme énergétique, Tissu adipeux.
- microbiologie : Dyslipidémies, Obésité.
- métabolisme : Acides gras volatils, Dyslipidémies, Obésité.
- pharmacologie : Agents antiobésité, Hypolipémiants, Médicaments issus de plantes chinoises.
- traitement médicamenteux : Dyslipidémies, Obésité.
- usage thérapeutique : Agents antiobésité, Hypolipémiants, Médicaments issus de plantes chinoises.
- Alimentation riche en graisse, Animaux, Microbiome gastro-intestinal, Mâle, Rat Sprague-Dawley.
English descriptors
- KwdEn :
- Adipose Tissue (drug effects), Adipose Tissue (pathology), Animals (MeSH), Anti-Obesity Agents (pharmacology), Anti-Obesity Agents (therapeutic use), Diet, High-Fat (MeSH), Drugs, Chinese Herbal (pharmacology), Drugs, Chinese Herbal (therapeutic use), Dyslipidemias (drug therapy), Dyslipidemias (metabolism), Dyslipidemias (microbiology), Dyslipidemias (pathology), Energy Metabolism (drug effects), Fatty Acids, Volatile (metabolism), Gastrointestinal Microbiome (MeSH), Hypolipidemic Agents (pharmacology), Hypolipidemic Agents (therapeutic use), Liver (drug effects), Liver (pathology), Male (MeSH), Obesity (drug therapy), Obesity (metabolism), Obesity (microbiology), Obesity (pathology), Rats, Sprague-Dawley (MeSH).
- MESH :
- chemical , metabolism : Fatty Acids, Volatile.
- chemical , pharmacology : Anti-Obesity Agents, Drugs, Chinese Herbal, Hypolipidemic Agents.
- drug effects : Adipose Tissue, Energy Metabolism, Liver.
- drug therapy : Dyslipidemias, Obesity.
- metabolism : Dyslipidemias, Obesity.
- microbiology : Dyslipidemias, Obesity.
- pathology : Adipose Tissue, Dyslipidemias, Liver, Obesity.
- chemical , therapeutic use : Anti-Obesity Agents, Drugs, Chinese Herbal, Hypolipidemic Agents.
- Animals, Diet, High-Fat, Gastrointestinal Microbiome, Male, Rats, Sprague-Dawley.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE
Traditional herbal medicine has been taken as a new and effective approach to treat many chronic diseases. Xiexin Tang (XXT), a compound recipe composed of Dahuang (Rheum palmatum L.), Huangqin (Scutellaria baicalensis Georgi) and Huanglian (Coptis chinensis Franch.), has been reported to have hypoglycemic and hypolipidemic effects, but its mechanism remains unclear. Our previous study found that Xiexin Tang markedly ameliorated the composition of the gut microbiota, especially for some short chain fatty acids (SCFAs) producing bacteria, and then notably increased SCFAs production. However, the mechanism of XXT on the fermentation of gut bacteria and further improvement of obesity is not yet clear.
AIM OF THE STUDY
This study aimed to unravel the molecular mechanism of XXT on the amelioration of obesity.
MATERIALS AND METHODS
Here, high-fat diet-induced obese rat model was established to investigate the intervention efficacy following oral administration of XXT. Additionally, the expressions of key enzymes of gut microbe-derived SCFAs biosynthesis and key targets in the signaling pathway of energy metabolism were investigated by ELISA and qPCR analysis.
RESULTS
Results showed that XXT could notably correct lipid metabolism disorders, alleviate systematic inflammation, improve insulin sensitivity and reduce fat accumulation. Additionally, XXT could increase gut microbiota-derived SCFAs-producing capacity by enhancing mRNA levels and activities of SCFA-synthetic key enzymes such as acetate kinase (ACK), methylmalonyl-CoA decarboxylase (MMD), butyryl-CoA: acetate CoA transferase (BUT) and butyrate kinase (BUK), which markedly decreased the adenosine triphosphate (ATP) contents, elevated adenosine diphosphate (ADP) and adenosine monophosphate (AMP) levels and further lowered the energy charge (EC) in obese rats via activating peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)/uncoupling protein-2 (UCP-2) signaling pathway. What's more, XXT could notably ameliorate dyslipidemia via increasing the gene expression of 5'-AMP-activated protein kinase (AMPK) and blocking mammalian target of rapamycin (mTOR) signaling pathway.
CONCLUSIONS
Taken together, our data provided a novel insight into the role of XXT in losing weight from energy metabolism regulation, which unraveled the molecular mechanism of XXT on the alleviation of dyslipidemia and fat heterotopic accumulation. The study provided useful information for XXT in clinical application to treat obesity.
DOI: 10.1016/j.jep.2019.112032
PubMed: 31220598
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Xiexin Tang ameliorates dyslipidemia in high-fat diet-induced obese rats via elevating gut microbiota-derived short chain fatty acids production and adjusting energy metabolism.</title><author><name sortKey="Xiao, Suwei" sort="Xiao, Suwei" uniqKey="Xiao S" first="Suwei" last="Xiao">Suwei Xiao</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Zhimiao" sort="Zhang, Zhimiao" uniqKey="Zhang Z" first="Zhimiao" last="Zhang">Zhimiao Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Mengjun" sort="Chen, Mengjun" uniqKey="Chen M" first="Mengjun" last="Chen">Mengjun Chen</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Zou, Junfeng" sort="Zou, Junfeng" uniqKey="Zou J" first="Junfeng" last="Zou">Junfeng Zou</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Jiang, Shu" sort="Jiang, Shu" uniqKey="Jiang S" first="Shu" last="Jiang">Shu Jiang</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China. Electronic address: jiangshu2020@126.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Qian, Dawei" sort="Qian, Dawei" uniqKey="Qian D" first="Dawei" last="Qian">Dawei Qian</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Duan, Jinao" sort="Duan, Jinao" uniqKey="Duan J" first="Jinao" last="Duan">Jinao Duan</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China. Electronic address: dja@njutcm.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31220598</idno><idno type="pmid">31220598</idno><idno type="doi">10.1016/j.jep.2019.112032</idno><idno type="wicri:Area/Main/Corpus">000249</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000249</idno><idno type="wicri:Area/Main/Curation">000249</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000249</idno><idno type="wicri:Area/Main/Exploration">000249</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Xiexin Tang ameliorates dyslipidemia in high-fat diet-induced obese rats via elevating gut microbiota-derived short chain fatty acids production and adjusting energy metabolism.</title><author><name sortKey="Xiao, Suwei" sort="Xiao, Suwei" uniqKey="Xiao S" first="Suwei" last="Xiao">Suwei Xiao</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Zhimiao" sort="Zhang, Zhimiao" uniqKey="Zhang Z" first="Zhimiao" last="Zhang">Zhimiao Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Mengjun" sort="Chen, Mengjun" uniqKey="Chen M" first="Mengjun" last="Chen">Mengjun Chen</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Zou, Junfeng" sort="Zou, Junfeng" uniqKey="Zou J" first="Junfeng" last="Zou">Junfeng Zou</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Jiang, Shu" sort="Jiang, Shu" uniqKey="Jiang S" first="Shu" last="Jiang">Shu Jiang</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China. Electronic address: jiangshu2020@126.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Qian, Dawei" sort="Qian, Dawei" uniqKey="Qian D" first="Dawei" last="Qian">Dawei Qian</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author><author><name sortKey="Duan, Jinao" sort="Duan, Jinao" uniqKey="Duan J" first="Jinao" last="Duan">Jinao Duan</name><affiliation wicri:level="1"><nlm:affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China. Electronic address: dja@njutcm.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023</wicri:regionArea><wicri:noRegion>210023</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of ethnopharmacology</title><idno type="eISSN">1872-7573</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adipose Tissue (drug effects)</term><term>Adipose Tissue (pathology)</term><term>Animals (MeSH)</term><term>Anti-Obesity Agents (pharmacology)</term><term>Anti-Obesity Agents (therapeutic use)</term><term>Diet, High-Fat (MeSH)</term><term>Drugs, Chinese Herbal (pharmacology)</term><term>Drugs, Chinese Herbal (therapeutic use)</term><term>Dyslipidemias (drug therapy)</term><term>Dyslipidemias (metabolism)</term><term>Dyslipidemias (microbiology)</term><term>Dyslipidemias (pathology)</term><term>Energy Metabolism (drug effects)</term><term>Fatty Acids, Volatile (metabolism)</term><term>Gastrointestinal Microbiome (MeSH)</term><term>Hypolipidemic Agents (pharmacology)</term><term>Hypolipidemic Agents (therapeutic use)</term><term>Liver (drug effects)</term><term>Liver (pathology)</term><term>Male (MeSH)</term><term>Obesity (drug therapy)</term><term>Obesity (metabolism)</term><term>Obesity (microbiology)</term><term>Obesity (pathology)</term><term>Rats, Sprague-Dawley (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acides gras volatils (métabolisme)</term><term>Agents antiobésité (pharmacologie)</term><term>Agents antiobésité (usage thérapeutique)</term><term>Alimentation riche en graisse (MeSH)</term><term>Animaux (MeSH)</term><term>Dyslipidémies (anatomopathologie)</term><term>Dyslipidémies (microbiologie)</term><term>Dyslipidémies (métabolisme)</term><term>Dyslipidémies (traitement médicamenteux)</term><term>Foie (anatomopathologie)</term><term>Foie (effets des médicaments et des substances chimiques)</term><term>Hypolipémiants (pharmacologie)</term><term>Hypolipémiants (usage thérapeutique)</term><term>Microbiome gastro-intestinal (MeSH)</term><term>Mâle (MeSH)</term><term>Médicaments issus de plantes chinoises (pharmacologie)</term><term>Médicaments issus de plantes chinoises (usage thérapeutique)</term><term>Métabolisme énergétique (effets des médicaments et des substances chimiques)</term><term>Obésité (anatomopathologie)</term><term>Obésité (microbiologie)</term><term>Obésité (métabolisme)</term><term>Obésité (traitement médicamenteux)</term><term>Rat Sprague-Dawley (MeSH)</term><term>Tissu adipeux (anatomopathologie)</term><term>Tissu adipeux (effets des médicaments et des substances chimiques)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Fatty Acids, Volatile</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Obesity Agents</term><term>Drugs, Chinese Herbal</term><term>Hypolipidemic Agents</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Dyslipidémies</term><term>Foie</term><term>Obésité</term><term>Tissu adipeux</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Adipose Tissue</term><term>Energy Metabolism</term><term>Liver</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyslipidemias</term><term>Obesity</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Foie</term><term>Métabolisme énergétique</term><term>Tissu adipeux</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dyslipidemias</term><term>Obesity</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Dyslipidémies</term><term>Obésité</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Dyslipidemias</term><term>Obesity</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Acides gras volatils</term><term>Dyslipidémies</term><term>Obésité</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Adipose Tissue</term><term>Dyslipidemias</term><term>Liver</term><term>Obesity</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiobésité</term><term>Hypolipémiants</term><term>Médicaments issus de plantes chinoises</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Obesity Agents</term><term>Drugs, Chinese Herbal</term><term>Hypolipidemic Agents</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Dyslipidémies</term><term>Obésité</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiobésité</term><term>Hypolipémiants</term><term>Médicaments issus de plantes chinoises</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Diet, High-Fat</term><term>Gastrointestinal Microbiome</term><term>Male</term><term>Rats, Sprague-Dawley</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Alimentation riche en graisse</term><term>Animaux</term><term>Microbiome gastro-intestinal</term><term>Mâle</term><term>Rat Sprague-Dawley</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>ETHNOPHARMACOLOGICAL RELEVANCE</b></p><p>Traditional herbal medicine has been taken as a new and effective approach to treat many chronic diseases. Xiexin Tang (XXT), a compound recipe composed of Dahuang (Rheum palmatum L.), Huangqin (Scutellaria baicalensis Georgi) and Huanglian (Coptis chinensis Franch.), has been reported to have hypoglycemic and hypolipidemic effects, but its mechanism remains unclear. Our previous study found that Xiexin Tang markedly ameliorated the composition of the gut microbiota, especially for some short chain fatty acids (SCFAs) producing bacteria, and then notably increased SCFAs production. However, the mechanism of XXT on the fermentation of gut bacteria and further improvement of obesity is not yet clear.</p></div><div type="abstract" xml:lang="en"><p><b>AIM OF THE STUDY</b></p><p>This study aimed to unravel the molecular mechanism of XXT on the amelioration of obesity.</p></div><div type="abstract" xml:lang="en"><p><b>MATERIALS AND METHODS</b></p><p>Here, high-fat diet-induced obese rat model was established to investigate the intervention efficacy following oral administration of XXT. Additionally, the expressions of key enzymes of gut microbe-derived SCFAs biosynthesis and key targets in the signaling pathway of energy metabolism were investigated by ELISA and qPCR analysis.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Results showed that XXT could notably correct lipid metabolism disorders, alleviate systematic inflammation, improve insulin sensitivity and reduce fat accumulation. Additionally, XXT could increase gut microbiota-derived SCFAs-producing capacity by enhancing mRNA levels and activities of SCFA-synthetic key enzymes such as acetate kinase (ACK), methylmalonyl-CoA decarboxylase (MMD), butyryl-CoA: acetate CoA transferase (BUT) and butyrate kinase (BUK), which markedly decreased the adenosine triphosphate (ATP) contents, elevated adenosine diphosphate (ADP) and adenosine monophosphate (AMP) levels and further lowered the energy charge (EC) in obese rats via activating peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)/uncoupling protein-2 (UCP-2) signaling pathway. What's more, XXT could notably ameliorate dyslipidemia via increasing the gene expression of 5'-AMP-activated protein kinase (AMPK) and blocking mammalian target of rapamycin (mTOR) signaling pathway.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Taken together, our data provided a novel insight into the role of XXT in losing weight from energy metabolism regulation, which unraveled the molecular mechanism of XXT on the alleviation of dyslipidemia and fat heterotopic accumulation. The study provided useful information for XXT in clinical application to treat obesity.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31220598</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7573</ISSN><JournalIssue CitedMedium="Internet"><Volume>241</Volume><PubDate><Year>2019</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of ethnopharmacology</Title><ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation></Journal><ArticleTitle>Xiexin Tang ameliorates dyslipidemia in high-fat diet-induced obese rats via elevating gut microbiota-derived short chain fatty acids production and adjusting energy metabolism.</ArticleTitle><Pagination><MedlinePgn>112032</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0378-8741(19)31589-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2019.112032</ELocationID><Abstract><AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Traditional herbal medicine has been taken as a new and effective approach to treat many chronic diseases. Xiexin Tang (XXT), a compound recipe composed of Dahuang (Rheum palmatum L.), Huangqin (Scutellaria baicalensis Georgi) and Huanglian (Coptis chinensis Franch.), has been reported to have hypoglycemic and hypolipidemic effects, but its mechanism remains unclear. Our previous study found that Xiexin Tang markedly ameliorated the composition of the gut microbiota, especially for some short chain fatty acids (SCFAs) producing bacteria, and then notably increased SCFAs production. However, the mechanism of XXT on the fermentation of gut bacteria and further improvement of obesity is not yet clear.</AbstractText><AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">This study aimed to unravel the molecular mechanism of XXT on the amelioration of obesity.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Here, high-fat diet-induced obese rat model was established to investigate the intervention efficacy following oral administration of XXT. Additionally, the expressions of key enzymes of gut microbe-derived SCFAs biosynthesis and key targets in the signaling pathway of energy metabolism were investigated by ELISA and qPCR analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Results showed that XXT could notably correct lipid metabolism disorders, alleviate systematic inflammation, improve insulin sensitivity and reduce fat accumulation. Additionally, XXT could increase gut microbiota-derived SCFAs-producing capacity by enhancing mRNA levels and activities of SCFA-synthetic key enzymes such as acetate kinase (ACK), methylmalonyl-CoA decarboxylase (MMD), butyryl-CoA: acetate CoA transferase (BUT) and butyrate kinase (BUK), which markedly decreased the adenosine triphosphate (ATP) contents, elevated adenosine diphosphate (ADP) and adenosine monophosphate (AMP) levels and further lowered the energy charge (EC) in obese rats via activating peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α)/uncoupling protein-2 (UCP-2) signaling pathway. What's more, XXT could notably ameliorate dyslipidemia via increasing the gene expression of 5'-AMP-activated protein kinase (AMPK) and blocking mammalian target of rapamycin (mTOR) signaling pathway.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Taken together, our data provided a novel insight into the role of XXT in losing weight from energy metabolism regulation, which unraveled the molecular mechanism of XXT on the alleviation of dyslipidemia and fat heterotopic accumulation. The study provided useful information for XXT in clinical application to treat obesity.</AbstractText><CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Suwei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhimiao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mengjun</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Junfeng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China. Electronic address: jiangshu2020@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Dawei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Jinao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, PR China. Electronic address: dja@njutcm.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>J Ethnopharmacol</MedlineTA><NlmUniqueID>7903310</NlmUniqueID><ISSNLinking>0378-8741</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019440">Anti-Obesity Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005232">Fatty Acids, Volatile</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000960">Hypolipidemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C518364">Xiexin decoction</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="N">Adipose Tissue</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019440" MajorTopicYN="N">Anti-Obesity Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059305" MajorTopicYN="N">Diet, High-Fat</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="N">Dyslipidemias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005232" MajorTopicYN="N">Fatty Acids, Volatile</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000960" MajorTopicYN="N">Hypolipidemic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="N">Obesity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMPK</Keyword><Keyword MajorTopicYN="N">Energy metabolism</Keyword><Keyword MajorTopicYN="N">Lipid metabolism</Keyword><Keyword MajorTopicYN="N">Obesity</Keyword><Keyword MajorTopicYN="N">SCFAs</Keyword><Keyword MajorTopicYN="N">Xiexin tang</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31220598</ArticleId><ArticleId IdType="pii">S0378-8741(19)31589-2</ArticleId><ArticleId IdType="doi">10.1016/j.jep.2019.112032</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Xiao, Suwei" sort="Xiao, Suwei" uniqKey="Xiao S" first="Suwei" last="Xiao">Suwei Xiao</name></noRegion><name sortKey="Chen, Mengjun" sort="Chen, Mengjun" uniqKey="Chen M" first="Mengjun" last="Chen">Mengjun Chen</name><name sortKey="Duan, Jinao" sort="Duan, Jinao" uniqKey="Duan J" first="Jinao" last="Duan">Jinao Duan</name><name sortKey="Jiang, Shu" sort="Jiang, Shu" uniqKey="Jiang S" first="Shu" last="Jiang">Shu Jiang</name><name sortKey="Qian, Dawei" sort="Qian, Dawei" uniqKey="Qian D" first="Dawei" last="Qian">Dawei Qian</name><name sortKey="Zhang, Zhimiao" sort="Zhang, Zhimiao" uniqKey="Zhang Z" first="Zhimiao" last="Zhang">Zhimiao Zhang</name><name sortKey="Zou, Junfeng" sort="Zou, Junfeng" uniqKey="Zou J" first="Junfeng" last="Zou">Junfeng Zou</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000181 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000181 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31220598
|texte= Xiexin Tang ameliorates dyslipidemia in high-fat diet-induced obese rats via elevating gut microbiota-derived short chain fatty acids production and adjusting energy metabolism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31220598" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |